References:
Aggarwal et. al. (2009, June). Medicinal Use of Cannabis in the United States: Historical
Perspectives, Current Trends, and Future Directions. Journal of Opioid Management, 5(3), 153-68.
Cardinale, A. (2014, January 14). A Brief History of How Marijuana Became Illegal in the U.S.
Retrieved July 16, 2014, from http://mic.com/articles/78685/a-brief-history-of-how-marijuana-became-illegal-in-the-u-s
"Marijuana Timeline." (n.d.). PBS -- Frontline. Retrieved July 16, 2014, from http://www.pbs.org/wgbh/pages/frontline/shows/dope/etc./cron.html
Villacorte, C. (2013, August 11). Marijuana History in United States Sees Milestone, Pot First
Banned In California 100 Years Ago. The Huffington Post. Retrieved July 16, 2014, from http://www.huffingtonpost.com/2013/08/11/marijuana-history-united-states_n_3736586.html
Wing, N. (2014, January 8). The Future of Legal Weed Is Bright. Here's Where It's Headed
Next. The Huffington Post. Retrieved July 16, 2014, from http://www.huffingtonpost.com/2014/01/08/legal-weed-next_n_4557583.html
References
Connecticut Department of Mental Health and Addiction Services (CDMHAS). (n.d.). Drugs with addictive potential. Retrieved 08 March 2012 from: http://www.ctclearinghouse.org/topics/customer-files/Drugs-with-Addictive-Potential-071105.pdf
Coon, D., & Mitterer, J. (2009). Psychology: A journey. (1st ed.). Belmont, CA: Wadsworth.
Fernandez, G., Rodriguez, O., & Villa, R. (2011). Neuropsychology and drug addiction. Papeles del Psicologo, 32(2), 159-165.
Hyman, S., & Malenka, R. (2001). Addiction and the brain: The neurobiology of compulsion and its persistence. Neuroscience, 2, 695-703.
Joseph, D.U.S. Department of Justice, Drug Enforcement Administration. (2005). Drugs of abuse. Retrieved from website: http://www.justice.gov/dea/pubs/abuse/doa-p.pdf
U.S. Department of health and Human Services, Substance Abuse and Mental Health Services Administration. (2006). Prescription medications: Misuse, abuse, dependence, and addiction. Substance Abuse Treatment Advisory, 5(2), 1-4. Retrieved from: http://kap.samhsa.gov/products/manuals/advisory/pdfs/prescription-meds.pdf
U.S. Department of Health and Human Services, National Institute of Drug Abuse. (2007). Drugs, brains, and behavior, the science of addiction (NIH Pub No. 07-5605).
References
Lichtenstein, P., Yip, B., Bjaerk, C., Pawitan, Y., Cannon, T., Sullivan, P. & Hultman. C. (2009). Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. The Lancet, 373(9659), 234-39.
Merikangas, R., Akiskal, H., Angst, J., Greenberg, P., Hirschfield, R., Petukhova, M. & Kessler, D. (2007). Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication. Archives of General Psychiatry 64(5), 543-52.
Miklowitz, D. (2007). The Role of the Family in the Course and Treatment of Bipolar Disorder. Current Directions in Psychological Science, 16(4), 192-6.
Miller, I., Keitner, G., Ryan, C., Uebelacker, L., Johnson, S. & Solomon, D. (2008). Family Treatment for Bipolar Disorder: Family Impairment by Treatment Interactions. Journal of Clinical Psychiatry, 69(5), 732-40.
Moreno, C., Laje, G., Blanco, C., Jiang, H., Schmidt, A. & Olfson, M. (2007). National Trends in the Outpatient Diagnosis and Treatment of Bipolar Disorder in Youth. Archives of general psychiatry, 64(9), 1032-9.
Muller, D., de Luca, V., Sicard, T., King, N., Strauss, J. & Kennedy, J. (2006). Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder. The British Journal of Psychiatry, 189, 317-23.
Pandey, G., Rizavi, H., Dwivedi, Y. & Pavuluri, M. (2008). Brain-Derived Neurotrophic Factor Gene Expression in Pediatric Bipolar Disorder: Effects of Treatment and Clinical Response. Child & Adolescent Psychiatry 47(9), 1077-85.
Phillips, M., Travis, M., Fagioloni, A. & Kupfer, D. (2008). Medication Effects in Neuroimaging Studies of Bipolar Disorder. American Journal of Psychiatry 165, 313-20.
Post, R. & Leverich, G. (2007). The Role of Psychosocial Stress in the Onset and Progression of Bipolar Disorder and its Comorbidities: The Need for Earlier and Alternative Modes of Therapeutic Intervention. Focus 5, 73-97.
Strakowski, S., DelBello, M., Fleck, D., Adler, C., Anthenelli, R., Keck, P., Arnold, L. & Amicone, J. (2007). Effects of Co-occurring Cannabis Use Disorders on the Course of Bipolar Disorder After a First Hospitalization for Mania. Archives of General Psychiatry, 64(1), 57-64.
Glick, Ira D. (2010) Undiagnosed Biplar Disorders: New Symdromes and New Testament.
Works Cited
Bolla, K., Brown, K., Eldreth, D., Tate, B., and Cadet, J. (2002). Dose-related neurocognitive effects of marijuana use. Neurology 59:1337-1343.
Farthing, G. (1992) The Psychology of Consciousness. Prentice Hall
Gazzaniga, M., Ivry R., and Mangun, G. (1998) Cognitive Neuroscience: The Biology of the Mind W.W. Norton & Company.
Grant, I., Gonzalez, R., Carey, C., Natatajan, L., and Wolfson, T. (2003). Non-acute (residual) neurocognitive effects of cannabis use: A meta-analytic study.
Journal of the International Neuropsychological Society. 9: 679.
Jorda, M., Ravman, N., Tas, M., Verbkel, S., Battista, N., van Lom, K., Lowenberg, B., Maccarrone, M., and Delwel, R. (2004). The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neurophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. Blood 104 92); 526-534.
Kamprath, K., Marsciano, G., Tang, J., Monory, K., Bisogno, T., Di Marzo, V., Lutz, B., and Wotjak, C. (2006). Cannabinoid CB1 Receptor Mediates Fear Extinction via Habituation-Like Processes. The Journal of Neuroscience 26(25): 6677-6686.
Kim, S., Won, S., Mao, X., Ledent, C., Jin, K. And Greenberg, D. (2006). Role for Neuronal Nitric-Oxide Synthase in Cannabinoid-Induced Neurogenesis. J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 150-154
Kogan, N., Blazquez, C., Alvarex, L., Gallily, R., Schlesinger, M., Guzman, A., and Mechoulam, R. (2006). A Cannabinoid Quinone Inhibits Angiogenesis by Targeting Vascular Endothelial Cells. Mol Pharmacol 70:51-59.
Lundqvist, T. (2005). Cognitive Consequences of Cannabis Use: Comparison with use of Stimulants and heroin with regard to attention, memory and executive functions. Pharmacology, Biochemistry and Behavior. 81: 319-330.
Maccarrone, M., Lorenzon, T., Bari, M., Melino, G., and Finazzi-Agro, A. (2000). Anandamide Induces Apoptosis in Human Cells via Vanilloid Receptors
Evidence For A Protective Role Of Cannabinoid Receptors. J. Biol. Chem., 275 (41): 31938-31945.
Massi, P., Vaccani, A., Ceruti, S., Colombo, S., Abbracchio, M., and Parolaro, D. (2004). Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines. JPET 308:838-845. CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity. Science 302 (5642): 84-88.
Murray, J. (1985). Marijuana's Effects on Human Cognitive Functions, Psychomotor Functions, and Personality. The Journal of General Psychology 113(1): 23-55.
Pacher, P., Batkai, S., and Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58(3): 389-462.
Pope, H. (2002). Cannabis, Cognition, and Residual Confounding. JAMA. 287 (9):1172-1174.
Robbe, D., Montgomery, S., Thome, A., Rueda-Orozsco, P., McNaughton, B., and Buzsaki, G. (2006). Cannabinoids reveal importance of spike timing coordination in hippocampal function Nature Neuroscience 9: 1526-33.
Rueda, D., Navarro, B., Martinez-Serrano, A., Guzman, M., and Galve-Roperh, I. (2002). The Endocannabinoid Anandamide Inhibits Neuronal Progenitor Cell Differentiation through Attenuation of the Rap1/B-Raf/ERK Pathway. J. Biol. Chem., November 22, 2002; 277(48): 46645-46650.
Sarfaraz, S., Afaq, F., Adhami, V. And Mukhtar, V. (2005). Cannabinoid Receptor as a Novel Target for the Treatment of Prostate Cancer. Cancer Research. 65: 1635-1641.
Solowij, N., Stephens, R., Roffman, R., Babor, T., Kadden, R., Miller, M., Christiansen, K., McRee, B., and Vendetti, J. (2002). Cognitive Functioning of Long-term Heavy Cannabis Users Seeking Treatment. JAMA. 2002; 287 (9):1123-1131.
The British Journal of Psychiatry (2001) 178: 101-106.